Corpus
PascalFrancis
Racine
Corpus
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease

Identifieur interne : 000947 ( PascalFrancis/Corpus ); précédent : 000946; suivant : 000948

PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease

Auteurs : D. J. Doudet ; M. L. Cornfeldt ; C. R. Honey ; A. W. Schweikert ; R. C. Allen

Source :

RBID : Pascal:05-0004448

Descripteurs français

English descriptors

Abstract

Human retinal pigment epithelial (hRPE) cells produce L-dopa, are easily harvested and expanded in culture, and, attached to microcarriers, can survive in the brain without immunosuppression. Studies in rats, primates, and parkinsonian patients have demonstrated that striatally implanted hRPE cells attached to gelatin microcarriers (RPE-GM) are able to improve parkinsonian symptoms and are well tolerated for extended periods. In moderately to severely impaired monkeys with bilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP)-induced parkinsonism receiving a unilateral RPE-GM implant in the putamen, there was a 39% improvement in clinical scores over the first 2 months post-implant. Positron emission tomography (PET) with [18F]fluoro-L-dopa (FDOPA) showed increased accumulation in the implanted putamen and a concomitant decrease in [11C]raclopride binding in the same area, suggesting increased dopamine release compared to the contralateral putamen. We report the first in vivo visualization of hRPE cells and their effects, implicating a dopaminergic mechanism of action.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0014-4886
A02 01      @0 EXNEAC
A03   1    @0 Exp. neurol. : (Print)
A05       @2 189
A06       @2 2
A08 01  1  ENG  @1 PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease
A11 01  1    @1 DOUDET (D. J.)
A11 02  1    @1 CORNFELDT (M. L.)
A11 03  1    @1 HONEY (C. R.)
A11 04  1    @1 SCHWEIKERT (A. W.)
A11 05  1    @1 ALLEN (R. C.)
A14 01      @1 Pacific Parkinson Research Centre, Department of Medicine/Neurology, University of British Columbia @2 Vancouver, BC, V6T 2B5 @3 CAN @Z 1 aut.
A14 02      @1 Cell Therapy, Titan Pharmaceuticals, Inc. @2 Somerville, NJ 08876 @3 USA @Z 2 aut. @Z 4 aut. @Z 5 aut.
A14 03      @1 Department of Surgery/Neurosurgery, University of British Columbia @2 Vancouver, BC, V6T 2B5 @3 CAN @Z 3 aut.
A20       @1 361-368
A21       @1 2004
A23 01      @0 ENG
A43 01      @1 INIST @2 9181 @5 354000122389610150
A44       @0 0000 @1 © 2005 INIST-CNRS. All rights reserved.
A45       @0 20 ref.
A47 01  1    @0 05-0004448
A60       @1 P
A61       @0 A
A64 01  1    @0 Experimental neurology : (Print)
A66 01      @0 USA
C01 01    ENG  @0 Human retinal pigment epithelial (hRPE) cells produce L-dopa, are easily harvested and expanded in culture, and, attached to microcarriers, can survive in the brain without immunosuppression. Studies in rats, primates, and parkinsonian patients have demonstrated that striatally implanted hRPE cells attached to gelatin microcarriers (RPE-GM) are able to improve parkinsonian symptoms and are well tolerated for extended periods. In moderately to severely impaired monkeys with bilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP)-induced parkinsonism receiving a unilateral RPE-GM implant in the putamen, there was a 39% improvement in clinical scores over the first 2 months post-implant. Positron emission tomography (PET) with [18F]fluoro-L-dopa (FDOPA) showed increased accumulation in the implanted putamen and a concomitant decrease in [11C]raclopride binding in the same area, suggesting increased dopamine release compared to the contralateral putamen. We report the first in vivo visualization of hRPE cells and their effects, implicating a dopaminergic mechanism of action.
C02 01  X    @0 002B17G
C02 02  X    @0 002B02U01
C03 01  X  FRE  @0 Parkinson maladie @5 01
C03 01  X  ENG  @0 Parkinson disease @5 01
C03 01  X  SPA  @0 Parkinson enfermedad @5 01
C03 02  X  FRE  @0 Tomoscintigraphie @5 02
C03 02  X  ENG  @0 Emission tomography @5 02
C03 02  X  SPA  @0 Tomocentelleografía @5 02
C03 03  X  FRE  @0 Positon @5 03
C03 03  X  ENG  @0 Positron @5 03
C03 03  X  SPA  @0 Positrón @5 03
C03 04  X  FRE  @0 Parkinsonisme @2 NM @5 04
C03 04  X  ENG  @0 Parkinsonism @2 NM @5 04
C03 04  X  SPA  @0 Parkinson síndrome @2 NM @5 04
C03 05  X  FRE  @0 Exploration radioisotopique @5 05
C03 05  X  ENG  @0 Radionuclide study @5 05
C03 05  X  SPA  @0 Exploración radioisotópica @5 05
C03 06  X  FRE  @0 Tomographie émission positon @5 06
C03 06  X  ENG  @0 Positron emission tomography @5 06
C03 06  X  SPA  @0 Tomografía emisión positrones @5 06
C03 07  X  FRE  @0 Implant @5 08
C03 07  X  ENG  @0 Implant @5 08
C03 07  X  SPA  @0 Implante @5 08
C03 08  X  FRE  @0 Homme @5 09
C03 08  X  ENG  @0 Human @5 09
C03 08  X  SPA  @0 Hombre @5 09
C03 09  X  FRE  @0 Rétine @5 11
C03 09  X  ENG  @0 Retina @5 11
C03 09  X  SPA  @0 Retina @5 11
C03 10  X  FRE  @0 Pigment @5 12
C03 10  X  ENG  @0 Pigments @5 12
C03 10  X  SPA  @0 Pigmento @5 12
C03 11  X  FRE  @0 Cellule épithéliale @5 14
C03 11  X  ENG  @0 Epithelial cell @5 14
C03 11  X  SPA  @0 Célula epitelial @5 14
C03 12  X  FRE  @0 Primates @2 NS @5 15
C03 12  X  ENG  @0 Primates @2 NS @5 15
C03 12  X  SPA  @0 Primates @2 NS @5 15
C03 13  X  FRE  @0 Modèle @5 17
C03 13  X  ENG  @0 Models @5 17
C03 13  X  SPA  @0 Modelo @5 17
C03 14  X  FRE  @0 Lévodopa @2 NK @2 FR @5 18
C03 14  X  ENG  @0 Levodopa @2 NK @2 FR @5 18
C03 14  X  SPA  @0 Levodopa @2 NK @2 FR @5 18
C03 15  X  FRE  @0 Immunodépression @5 19
C03 15  X  ENG  @0 Immunosuppression @5 19
C03 15  X  SPA  @0 Inmunodepresión @5 19
C03 16  X  FRE  @0 Animal @5 20
C03 16  X  ENG  @0 Animal @5 20
C03 16  X  SPA  @0 Animal @5 20
C03 17  X  FRE  @0 Rat @5 21
C03 17  X  ENG  @0 Rat @5 21
C03 17  X  SPA  @0 Rata @5 21
C03 18  X  FRE  @0 Gélatine @5 22
C03 18  X  ENG  @0 Gelatin @5 22
C03 18  X  SPA  @0 Gelatina @5 22
C03 19  X  FRE  @0 Singe @5 23
C03 19  X  ENG  @0 Monkey @5 23
C03 19  X  SPA  @0 Mono @5 23
C03 20  X  FRE  @0 Putamen @5 24
C03 20  X  ENG  @0 Putamen @5 24
C03 20  X  SPA  @0 Putamen @5 24
C03 21  X  FRE  @0 Amélioration @5 35
C03 21  X  ENG  @0 Improvement @5 35
C03 21  X  SPA  @0 Mejora @5 35
C07 01  X  FRE  @0 Mammalia @2 NS
C07 01  X  ENG  @0 Mammalia @2 NS
C07 01  X  SPA  @0 Mammalia @2 NS
C07 02  X  FRE  @0 Vertebrata @2 NS
C07 02  X  ENG  @0 Vertebrata @2 NS
C07 02  X  SPA  @0 Vertebrata @2 NS
C07 03  X  FRE  @0 Rodentia @2 NS
C07 03  X  ENG  @0 Rodentia @2 NS
C07 03  X  SPA  @0 Rodentia @2 NS
C07 04  X  FRE  @0 Encéphale pathologie @5 37
C07 04  X  ENG  @0 Cerebral disorder @5 37
C07 04  X  SPA  @0 Encéfalo patología @5 37
C07 05  X  FRE  @0 Appareil visuel @5 38
C07 05  X  ENG  @0 Visual system @5 38
C07 05  X  SPA  @0 Aparato visual @5 38
C07 06  X  FRE  @0 Oeil @5 39
C07 06  X  ENG  @0 Eye @5 39
C07 06  X  SPA  @0 Ojo @5 39
C07 07  X  FRE  @0 Extrapyramidal syndrome @5 40
C07 07  X  ENG  @0 Extrapyramidal syndrome @5 40
C07 07  X  SPA  @0 Extrapiramidal síndrome @5 40
C07 08  X  FRE  @0 Maladie dégénérative @5 41
C07 08  X  ENG  @0 Degenerative disease @5 41
C07 08  X  SPA  @0 Enfermedad degenerativa @5 41
C07 09  X  FRE  @0 Système nerveux central pathologie @5 42
C07 09  X  ENG  @0 Central nervous system disease @5 42
C07 09  X  SPA  @0 Sistema nervosio central patología @5 42
C07 10  X  FRE  @0 Système nerveux pathologie @5 43
C07 10  X  ENG  @0 Nervous system diseases @5 43
C07 10  X  SPA  @0 Sistema nervioso patología @5 43
C07 11  X  FRE  @0 Antiparkinsonien @5 45
C07 11  X  ENG  @0 Antiparkinson agent @5 45
C07 11  X  SPA  @0 Antiparkinsoniano @5 45
C07 12  X  FRE  @0 Catécholamine @5 46
C07 12  X  ENG  @0 Catecholamine @5 46
C07 12  X  SPA  @0 Catecolamina @5 46
C07 13  X  FRE  @0 Neurotransmetteur @5 47
C07 13  X  ENG  @0 Neurotransmitter @5 47
C07 13  X  SPA  @0 Neurotransmisor @5 47
C07 14  X  FRE  @0 Chirurgie @5 48
C07 14  X  ENG  @0 Surgery @5 48
C07 14  X  SPA  @0 Cirugía @5 48
C07 15  X  FRE  @0 Greffe @5 49
C07 15  X  ENG  @0 Graft @5 49
C07 15  X  SPA  @0 Injerto @5 49
N21       @1 004
N44 01      @1 OTO
N82       @1 OTO

Format Inist (serveur)

NO : PASCAL 05-0004448 INIST
ET : PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease
AU : DOUDET (D. J.); CORNFELDT (M. L.); HONEY (C. R.); SCHWEIKERT (A. W.); ALLEN (R. C.)
AF : Pacific Parkinson Research Centre, Department of Medicine/Neurology, University of British Columbia/Vancouver, BC, V6T 2B5/Canada (1 aut.); Cell Therapy, Titan Pharmaceuticals, Inc./Somerville, NJ 08876/Etats-Unis (2 aut., 4 aut., 5 aut.); Department of Surgery/Neurosurgery, University of British Columbia/Vancouver, BC, V6T 2B5/Canada (3 aut.)
DT : Publication en série; Niveau analytique
SO : Experimental neurology : (Print); ISSN 0014-4886; Coden EXNEAC; Etats-Unis; Da. 2004; Vol. 189; No. 2; Pp. 361-368; Bibl. 20 ref.
LA : Anglais
EA : Human retinal pigment epithelial (hRPE) cells produce L-dopa, are easily harvested and expanded in culture, and, attached to microcarriers, can survive in the brain without immunosuppression. Studies in rats, primates, and parkinsonian patients have demonstrated that striatally implanted hRPE cells attached to gelatin microcarriers (RPE-GM) are able to improve parkinsonian symptoms and are well tolerated for extended periods. In moderately to severely impaired monkeys with bilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP)-induced parkinsonism receiving a unilateral RPE-GM implant in the putamen, there was a 39% improvement in clinical scores over the first 2 months post-implant. Positron emission tomography (PET) with [18F]fluoro-L-dopa (FDOPA) showed increased accumulation in the implanted putamen and a concomitant decrease in [11C]raclopride binding in the same area, suggesting increased dopamine release compared to the contralateral putamen. We report the first in vivo visualization of hRPE cells and their effects, implicating a dopaminergic mechanism of action.
CC : 002B17G; 002B02U01
FD : Parkinson maladie; Tomoscintigraphie; Positon; Parkinsonisme; Exploration radioisotopique; Tomographie émission positon; Implant; Homme; Rétine; Pigment; Cellule épithéliale; Primates; Modèle; Lévodopa; Immunodépression; Animal; Rat; Gélatine; Singe; Putamen; Amélioration
FG : Mammalia; Vertebrata; Rodentia; Encéphale pathologie; Appareil visuel; Oeil; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie; Antiparkinsonien; Catécholamine; Neurotransmetteur; Chirurgie; Greffe
ED : Parkinson disease; Emission tomography; Positron; Parkinsonism; Radionuclide study; Positron emission tomography; Implant; Human; Retina; Pigments; Epithelial cell; Primates; Models; Levodopa; Immunosuppression; Animal; Rat; Gelatin; Monkey; Putamen; Improvement
EG : Mammalia; Vertebrata; Rodentia; Cerebral disorder; Visual system; Eye; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases; Antiparkinson agent; Catecholamine; Neurotransmitter; Surgery; Graft
SD : Parkinson enfermedad; Tomocentelleografía; Positrón; Parkinson síndrome; Exploración radioisotópica; Tomografía emisión positrones; Implante; Hombre; Retina; Pigmento; Célula epitelial; Primates; Modelo; Levodopa; Inmunodepresión; Animal; Rata; Gelatina; Mono; Putamen; Mejora
LO : INIST-9181.354000122389610150
ID : 05-0004448

Links to Exploration step

Pascal:05-0004448

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease</title>
<author>
<name sortKey="Doudet, D J" sort="Doudet, D J" uniqKey="Doudet D" first="D. J." last="Doudet">D. J. Doudet</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Pacific Parkinson Research Centre, Department of Medicine/Neurology, University of British Columbia</s1>
<s2>Vancouver, BC, V6T 2B5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Cornfeldt, M L" sort="Cornfeldt, M L" uniqKey="Cornfeldt M" first="M. L." last="Cornfeldt">M. L. Cornfeldt</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Cell Therapy, Titan Pharmaceuticals, Inc.</s1>
<s2>Somerville, NJ 08876</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Honey, C R" sort="Honey, C R" uniqKey="Honey C" first="C. R." last="Honey">C. R. Honey</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Department of Surgery/Neurosurgery, University of British Columbia</s1>
<s2>Vancouver, BC, V6T 2B5</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Schweikert, A W" sort="Schweikert, A W" uniqKey="Schweikert A" first="A. W." last="Schweikert">A. W. Schweikert</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Cell Therapy, Titan Pharmaceuticals, Inc.</s1>
<s2>Somerville, NJ 08876</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Allen, R C" sort="Allen, R C" uniqKey="Allen R" first="R. C." last="Allen">R. C. Allen</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Cell Therapy, Titan Pharmaceuticals, Inc.</s1>
<s2>Somerville, NJ 08876</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">05-0004448</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 05-0004448 INIST</idno>
<idno type="RBID">Pascal:05-0004448</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000947</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease</title>
<author>
<name sortKey="Doudet, D J" sort="Doudet, D J" uniqKey="Doudet D" first="D. J." last="Doudet">D. J. Doudet</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Pacific Parkinson Research Centre, Department of Medicine/Neurology, University of British Columbia</s1>
<s2>Vancouver, BC, V6T 2B5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Cornfeldt, M L" sort="Cornfeldt, M L" uniqKey="Cornfeldt M" first="M. L." last="Cornfeldt">M. L. Cornfeldt</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Cell Therapy, Titan Pharmaceuticals, Inc.</s1>
<s2>Somerville, NJ 08876</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Honey, C R" sort="Honey, C R" uniqKey="Honey C" first="C. R." last="Honey">C. R. Honey</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Department of Surgery/Neurosurgery, University of British Columbia</s1>
<s2>Vancouver, BC, V6T 2B5</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Schweikert, A W" sort="Schweikert, A W" uniqKey="Schweikert A" first="A. W." last="Schweikert">A. W. Schweikert</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Cell Therapy, Titan Pharmaceuticals, Inc.</s1>
<s2>Somerville, NJ 08876</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Allen, R C" sort="Allen, R C" uniqKey="Allen R" first="R. C." last="Allen">R. C. Allen</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Cell Therapy, Titan Pharmaceuticals, Inc.</s1>
<s2>Somerville, NJ 08876</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Experimental neurology : (Print)</title>
<title level="j" type="abbreviated">Exp. neurol. : (Print)</title>
<idno type="ISSN">0014-4886</idno>
<imprint>
<date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Experimental neurology : (Print)</title>
<title level="j" type="abbreviated">Exp. neurol. : (Print)</title>
<idno type="ISSN">0014-4886</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animal</term>
<term>Emission tomography</term>
<term>Epithelial cell</term>
<term>Gelatin</term>
<term>Human</term>
<term>Immunosuppression</term>
<term>Implant</term>
<term>Improvement</term>
<term>Levodopa</term>
<term>Models</term>
<term>Monkey</term>
<term>Parkinson disease</term>
<term>Parkinsonism</term>
<term>Pigments</term>
<term>Positron</term>
<term>Positron emission tomography</term>
<term>Primates</term>
<term>Putamen</term>
<term>Radionuclide study</term>
<term>Rat</term>
<term>Retina</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Parkinson maladie</term>
<term>Tomoscintigraphie</term>
<term>Positon</term>
<term>Parkinsonisme</term>
<term>Exploration radioisotopique</term>
<term>Tomographie émission positon</term>
<term>Implant</term>
<term>Homme</term>
<term>Rétine</term>
<term>Pigment</term>
<term>Cellule épithéliale</term>
<term>Primates</term>
<term>Modèle</term>
<term>Lévodopa</term>
<term>Immunodépression</term>
<term>Animal</term>
<term>Rat</term>
<term>Gélatine</term>
<term>Singe</term>
<term>Putamen</term>
<term>Amélioration</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Human retinal pigment epithelial (hRPE) cells produce L-dopa, are easily harvested and expanded in culture, and, attached to microcarriers, can survive in the brain without immunosuppression. Studies in rats, primates, and parkinsonian patients have demonstrated that striatally implanted hRPE cells attached to gelatin microcarriers (RPE-GM) are able to improve parkinsonian symptoms and are well tolerated for extended periods. In moderately to severely impaired monkeys with bilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP)-induced parkinsonism receiving a unilateral RPE-GM implant in the putamen, there was a 39% improvement in clinical scores over the first 2 months post-implant. Positron emission tomography (PET) with [
<sup>18</sup>
F]fluoro-L-dopa (FDOPA) showed increased accumulation in the implanted putamen and a concomitant decrease in [
<sup>11</sup>
C]raclopride binding in the same area, suggesting increased dopamine release compared to the contralateral putamen. We report the first in vivo visualization of hRPE cells and their effects, implicating a dopaminergic mechanism of action.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0014-4886</s0>
</fA01>
<fA02 i1="01">
<s0>EXNEAC</s0>
</fA02>
<fA03 i2="1">
<s0>Exp. neurol. : (Print)</s0>
</fA03>
<fA05>
<s2>189</s2>
</fA05>
<fA06>
<s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>DOUDET (D. J.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>CORNFELDT (M. L.)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>HONEY (C. R.)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>SCHWEIKERT (A. W.)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>ALLEN (R. C.)</s1>
</fA11>
<fA14 i1="01">
<s1>Pacific Parkinson Research Centre, Department of Medicine/Neurology, University of British Columbia</s1>
<s2>Vancouver, BC, V6T 2B5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Cell Therapy, Titan Pharmaceuticals, Inc.</s1>
<s2>Somerville, NJ 08876</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Department of Surgery/Neurosurgery, University of British Columbia</s1>
<s2>Vancouver, BC, V6T 2B5</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20>
<s1>361-368</s1>
</fA20>
<fA21>
<s1>2004</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>9181</s2>
<s5>354000122389610150</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>20 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>05-0004448</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Experimental neurology : (Print)</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Human retinal pigment epithelial (hRPE) cells produce L-dopa, are easily harvested and expanded in culture, and, attached to microcarriers, can survive in the brain without immunosuppression. Studies in rats, primates, and parkinsonian patients have demonstrated that striatally implanted hRPE cells attached to gelatin microcarriers (RPE-GM) are able to improve parkinsonian symptoms and are well tolerated for extended periods. In moderately to severely impaired monkeys with bilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP)-induced parkinsonism receiving a unilateral RPE-GM implant in the putamen, there was a 39% improvement in clinical scores over the first 2 months post-implant. Positron emission tomography (PET) with [
<sup>18</sup>
F]fluoro-L-dopa (FDOPA) showed increased accumulation in the implanted putamen and a concomitant decrease in [
<sup>11</sup>
C]raclopride binding in the same area, suggesting increased dopamine release compared to the contralateral putamen. We report the first in vivo visualization of hRPE cells and their effects, implicating a dopaminergic mechanism of action.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Tomoscintigraphie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Emission tomography</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Tomocentelleografía</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Positon</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Positron</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Positrón</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Exploration radioisotopique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Radionuclide study</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Exploración radioisotópica</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Tomographie émission positon</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Positron emission tomography</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Tomografía emisión positrones</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Implant</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Implant</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Implante</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Homme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Human</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Hombre</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Rétine</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Retina</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Retina</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Pigment</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Pigments</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Pigmento</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Cellule épithéliale</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Epithelial cell</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Célula epitelial</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Primates</s0>
<s2>NS</s2>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Primates</s0>
<s2>NS</s2>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Primates</s0>
<s2>NS</s2>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE">
<s0>Modèle</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG">
<s0>Models</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA">
<s0>Modelo</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE">
<s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG">
<s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA">
<s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE">
<s0>Immunodépression</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG">
<s0>Immunosuppression</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA">
<s0>Inmunodepresión</s0>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE">
<s0>Animal</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG">
<s0>Animal</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA">
<s0>Animal</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE">
<s0>Rat</s0>
<s5>21</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG">
<s0>Rat</s0>
<s5>21</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA">
<s0>Rata</s0>
<s5>21</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE">
<s0>Gélatine</s0>
<s5>22</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG">
<s0>Gelatin</s0>
<s5>22</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA">
<s0>Gelatina</s0>
<s5>22</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE">
<s0>Singe</s0>
<s5>23</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG">
<s0>Monkey</s0>
<s5>23</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA">
<s0>Mono</s0>
<s5>23</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE">
<s0>Putamen</s0>
<s5>24</s5>
</fC03>
<fC03 i1="20" i2="X" l="ENG">
<s0>Putamen</s0>
<s5>24</s5>
</fC03>
<fC03 i1="20" i2="X" l="SPA">
<s0>Putamen</s0>
<s5>24</s5>
</fC03>
<fC03 i1="21" i2="X" l="FRE">
<s0>Amélioration</s0>
<s5>35</s5>
</fC03>
<fC03 i1="21" i2="X" l="ENG">
<s0>Improvement</s0>
<s5>35</s5>
</fC03>
<fC03 i1="21" i2="X" l="SPA">
<s0>Mejora</s0>
<s5>35</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Appareil visuel</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Visual system</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Aparato visual</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Oeil</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Eye</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Ojo</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE">
<s0>Système nerveux central pathologie</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>43</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE">
<s0>Antiparkinsonien</s0>
<s5>45</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG">
<s0>Antiparkinson agent</s0>
<s5>45</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA">
<s0>Antiparkinsoniano</s0>
<s5>45</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE">
<s0>Catécholamine</s0>
<s5>46</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG">
<s0>Catecholamine</s0>
<s5>46</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA">
<s0>Catecolamina</s0>
<s5>46</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE">
<s0>Neurotransmetteur</s0>
<s5>47</s5>
</fC07>
<fC07 i1="13" i2="X" l="ENG">
<s0>Neurotransmitter</s0>
<s5>47</s5>
</fC07>
<fC07 i1="13" i2="X" l="SPA">
<s0>Neurotransmisor</s0>
<s5>47</s5>
</fC07>
<fC07 i1="14" i2="X" l="FRE">
<s0>Chirurgie</s0>
<s5>48</s5>
</fC07>
<fC07 i1="14" i2="X" l="ENG">
<s0>Surgery</s0>
<s5>48</s5>
</fC07>
<fC07 i1="14" i2="X" l="SPA">
<s0>Cirugía</s0>
<s5>48</s5>
</fC07>
<fC07 i1="15" i2="X" l="FRE">
<s0>Greffe</s0>
<s5>49</s5>
</fC07>
<fC07 i1="15" i2="X" l="ENG">
<s0>Graft</s0>
<s5>49</s5>
</fC07>
<fC07 i1="15" i2="X" l="SPA">
<s0>Injerto</s0>
<s5>49</s5>
</fC07>
<fN21>
<s1>004</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
<server>
<NO>PASCAL 05-0004448 INIST</NO>
<ET>PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease</ET>
<AU>DOUDET (D. J.); CORNFELDT (M. L.); HONEY (C. R.); SCHWEIKERT (A. W.); ALLEN (R. C.)</AU>
<AF>Pacific Parkinson Research Centre, Department of Medicine/Neurology, University of British Columbia/Vancouver, BC, V6T 2B5/Canada (1 aut.); Cell Therapy, Titan Pharmaceuticals, Inc./Somerville, NJ 08876/Etats-Unis (2 aut., 4 aut., 5 aut.); Department of Surgery/Neurosurgery, University of British Columbia/Vancouver, BC, V6T 2B5/Canada (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Experimental neurology : (Print); ISSN 0014-4886; Coden EXNEAC; Etats-Unis; Da. 2004; Vol. 189; No. 2; Pp. 361-368; Bibl. 20 ref.</SO>
<LA>Anglais</LA>
<EA>Human retinal pigment epithelial (hRPE) cells produce L-dopa, are easily harvested and expanded in culture, and, attached to microcarriers, can survive in the brain without immunosuppression. Studies in rats, primates, and parkinsonian patients have demonstrated that striatally implanted hRPE cells attached to gelatin microcarriers (RPE-GM) are able to improve parkinsonian symptoms and are well tolerated for extended periods. In moderately to severely impaired monkeys with bilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP)-induced parkinsonism receiving a unilateral RPE-GM implant in the putamen, there was a 39% improvement in clinical scores over the first 2 months post-implant. Positron emission tomography (PET) with [
<sup>18</sup>
F]fluoro-L-dopa (FDOPA) showed increased accumulation in the implanted putamen and a concomitant decrease in [
<sup>11</sup>
C]raclopride binding in the same area, suggesting increased dopamine release compared to the contralateral putamen. We report the first in vivo visualization of hRPE cells and their effects, implicating a dopaminergic mechanism of action.</EA>
<CC>002B17G; 002B02U01</CC>
<FD>Parkinson maladie; Tomoscintigraphie; Positon; Parkinsonisme; Exploration radioisotopique; Tomographie émission positon; Implant; Homme; Rétine; Pigment; Cellule épithéliale; Primates; Modèle; Lévodopa; Immunodépression; Animal; Rat; Gélatine; Singe; Putamen; Amélioration</FD>
<FG>Mammalia; Vertebrata; Rodentia; Encéphale pathologie; Appareil visuel; Oeil; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie; Antiparkinsonien; Catécholamine; Neurotransmetteur; Chirurgie; Greffe</FG>
<ED>Parkinson disease; Emission tomography; Positron; Parkinsonism; Radionuclide study; Positron emission tomography; Implant; Human; Retina; Pigments; Epithelial cell; Primates; Models; Levodopa; Immunosuppression; Animal; Rat; Gelatin; Monkey; Putamen; Improvement</ED>
<EG>Mammalia; Vertebrata; Rodentia; Cerebral disorder; Visual system; Eye; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases; Antiparkinson agent; Catecholamine; Neurotransmitter; Surgery; Graft</EG>
<SD>Parkinson enfermedad; Tomocentelleografía; Positrón; Parkinson síndrome; Exploración radioisotópica; Tomografía emisión positrones; Implante; Hombre; Retina; Pigmento; Célula epitelial; Primates; Modelo; Levodopa; Inmunodepresión; Animal; Rata; Gelatina; Mono; Putamen; Mejora</SD>
<LO>INIST-9181.354000122389610150</LO>
<ID>05-0004448</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000947 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000947 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0004448
   |texte=   PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022